Amylyx Pharmaceuticals, Inc.
General ticker "AMLX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $557.3M (TTM average)
Amylyx Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 53.5%.
Estimated limits based on current volatility of 3.1%: low 13.72$, high 14.59$
Factors to consider:
- Total employees count: 123 (-68.0%) as of 2024
- Top business risk factors: Economic downturns and volatility, Labor/talent shortage/retention, Strategic risks and growth management, Market acceptance, Regulatory and compliance
- Current price 107.4% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.46$, 6.99$]
- 2025-12-31 to 2026-12-31 estimated range: [2.06$, 5.92$]
Financial Metrics affecting the AMLX estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -62.23 <= 0.33
- Positive: Investing cash flow per share per price, % of 28.08 > -0.66
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 85.09 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Inventory ratio change, % of -9.14 <= -0.75
Short-term AMLX quotes
Long-term AMLX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $22.23MM | $380.79MM | $87.37MM |
| Operating Expenses | $223.57MM | $341.98MM | $402.10MM |
| Operating Income | $-201.34MM | $38.80MM | $-314.73MM |
| Non-Operating Income | $3.74MM | $15.49MM | $12.60MM |
| R&D Expense | $93.45MM | $128.19MM | $140.29MM |
| Income(Loss) | $-197.60MM | $54.30MM | $-302.14MM |
| Taxes | $0.77MM | $5.03MM | $-0.39MM |
| Profit(Loss)* | $-198.38MM | $49.27MM | $-301.74MM |
| Stockholders Equity | $340.61MM | $433.43MM | $164.76MM |
| Inventory | $9.77MM | $38.32MM | $0.00MM |
| Assets | $391.45MM | $517.45MM | $193.63MM |
| Operating Cash Flow | $-179.87MM | $11.92MM | $-167.65MM |
| Capital expenditure | $2.53MM | $1.24MM | $0.16MM |
| Investing Cash Flow | $-238.99MM | $92.05MM | $75.65MM |
| Financing Cash Flow | $431.79MM | $3.54MM | $0.35MM |
| Earnings Per Share** | $-2.98 | $0.73 | $-4.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.